Ejaculation Frequency and Prostate Cancer: CAPLIFE Study

To evaluate the association between ejaculation frequency (EF) during four stages of life and prostate cancer (PCa) according to tumor aggressiveness, PCa stage, and urinary symptomatology. A total of 456 incident PCa cases histologically confirmed, and 427 controls aged 40-80 years from the CAPLIFE...

Full description

Saved in:
Bibliographic Details
Published inThe world journal of men's health Vol. 41; no. 3; pp. 724 - 733
Main Authors Lozano-Lorca, Macarena, Olmedo-Requena, Rocío, Barrios-Rodríguez, Rocío, Jiménez-Pacheco, Antonio, Vázquez-Alonso, Fernando, Castillo-Bueno, Helga-María, Rodríguez-Barranco, Miguel, Jiménez-Moleón, José Juan
Format Journal Article
LanguageEnglish
Published Korea (South) Korean Society for Sexual Medicine and Andrology 01.07.2023
Subjects
Alcohol
caplife study
case-control studies
Diabetes
ejaculation
Erectile dysfunction
Family medical history
Hospitals
Longitudinal studies
Original
Prostate cancer
Questionnaires
sexual activity
Sexual behavior
Sociodemographics
Tumors
Urology
Vasectomy
Case-control studies
Sexual activity
CAPLIFE study
Prostate cancer
Ejaculation
Online AccessGet full text
ISSN2287-4208
2287-4690
DOI10.5534/wjmh.220216

Cover

Abstract To evaluate the association between ejaculation frequency (EF) during four stages of life and prostate cancer (PCa) according to tumor aggressiveness, PCa stage, and urinary symptomatology. A total of 456 incident PCa cases histologically confirmed, and 427 controls aged 40-80 years from the CAPLIFE study were analyzed. This study is a population-based case-control study carried out in the south of Spain. Average EF was measured for: (1) 20s, (2) 30s, (3) 40s, and (4) one year before the interview. EF was categorized into: (1) 0-3, (2) 4, and (3) >4 ejaculations/month. Sociodemographic, lifestyle, and medical information were also collected. To estimate the association between EF and PCa, adjusted ORs (aORs) and 95% CIs were calculated by logistic regression models. A year before the interview, PCa cases ejaculated less frequently than the controls. An inverse association was observed between the EF a year before and PCa, aOR=1.64 (95% CI 1.03-2.61) for men with 4 ejaculations/month, and aOR=2.38 (95% CI 1.57-3.60) for men with 0-3 ejaculations/month, compared to men with >4. The association was higher for cases with ISUP 3-5 (aOR=2.76 [95% CI 1.34-5.67] for men with 0-3 ejaculations/month) or with a locally advanced-metastatic tumor (aOR=4.70 [95% CI 1.55-14.29]). Moreover, men with moderate urinary symptoms and 0-3 ejaculations/month had the highest risk, aOR=3.83 (95% CI 1.84-7.95). A low EF could be associated with a higher risk of PCa, especially for cases with ISUP 3-5 or with a locally advanced-metastatic tumor.
AbstractList Purpose: To evaluate the association between ejaculation frequency (EF) during four stages of life and prostate cancer (PCa) according to tumor aggressiveness, PCa stage, and urinary symptomatology. Materials and Methods: A total of 456 incident PCa cases histologically confirmed, and 427 controls aged 40–80 years from the CAPLIFE study were analyzed. This study is a population-based case-control study carried out in the south of Spain. Average EF was measured for: (1) 20s, (2) 30s, (3) 40s, and (4) one year before the interview. EF was categorized into: (1) 0–3, (2) 4, and (3) >4 ejaculations/month. Sociodemographic, lifestyle, and medical information were also collected. To estimate the association between EF and PCa, adjusted ORs (aORs) and 95% CIs were calculated by logistic regression models. Results: A year before the interview, PCa cases ejaculated less frequently than the controls. An inverse association was observed between the EF a year before and PCa, aOR=1.64 (95% CI 1.03–2.61) for men with 4 ejaculations/month, and aOR=2.38 (95% CI 1.57–3.60) for men with 0–3 ejaculations/month, compared to men with >4. The association was higher for cases with ISUP 3–5 (aOR=2.76 [95% CI 1.34–5.67] for men with 0–3 ejaculations/month) or with a locally advancedmetastatic tumor (aOR=4.70 [95% CI 1.55–14.29]). Moreover, men with moderate urinary symptoms and 0–3 ejaculations/ month had the highest risk, aOR=3.83 (95% CI 1.84–7.95). Conclusions: A low EF could be associated with a higher risk of PCa, especially for cases with ISUP 3–5 or with a locally advanced-metastatic tumor.
To evaluate the association between ejaculation frequency (EF) during four stages of life and prostate cancer (PCa) according to tumor aggressiveness, PCa stage, and urinary symptomatology.PURPOSETo evaluate the association between ejaculation frequency (EF) during four stages of life and prostate cancer (PCa) according to tumor aggressiveness, PCa stage, and urinary symptomatology.A total of 456 incident PCa cases histologically confirmed, and 427 controls aged 40-80 years from the CAPLIFE study were analyzed. This study is a population-based case-control study carried out in the south of Spain. Average EF was measured for: (1) 20s, (2) 30s, (3) 40s, and (4) one year before the interview. EF was categorized into: (1) 0-3, (2) 4, and (3) >4 ejaculations/month. Sociodemographic, lifestyle, and medical information were also collected. To estimate the association between EF and PCa, adjusted ORs (aORs) and 95% CIs were calculated by logistic regression models.MATERIALS AND METHODSA total of 456 incident PCa cases histologically confirmed, and 427 controls aged 40-80 years from the CAPLIFE study were analyzed. This study is a population-based case-control study carried out in the south of Spain. Average EF was measured for: (1) 20s, (2) 30s, (3) 40s, and (4) one year before the interview. EF was categorized into: (1) 0-3, (2) 4, and (3) >4 ejaculations/month. Sociodemographic, lifestyle, and medical information were also collected. To estimate the association between EF and PCa, adjusted ORs (aORs) and 95% CIs were calculated by logistic regression models.A year before the interview, PCa cases ejaculated less frequently than the controls. An inverse association was observed between the EF a year before and PCa, aOR=1.64 (95% CI 1.03-2.61) for men with 4 ejaculations/month, and aOR=2.38 (95% CI 1.57-3.60) for men with 0-3 ejaculations/month, compared to men with >4. The association was higher for cases with ISUP 3-5 (aOR=2.76 [95% CI 1.34-5.67] for men with 0-3 ejaculations/month) or with a locally advanced-metastatic tumor (aOR=4.70 [95% CI 1.55-14.29]). Moreover, men with moderate urinary symptoms and 0-3 ejaculations/month had the highest risk, aOR=3.83 (95% CI 1.84-7.95).RESULTSA year before the interview, PCa cases ejaculated less frequently than the controls. An inverse association was observed between the EF a year before and PCa, aOR=1.64 (95% CI 1.03-2.61) for men with 4 ejaculations/month, and aOR=2.38 (95% CI 1.57-3.60) for men with 0-3 ejaculations/month, compared to men with >4. The association was higher for cases with ISUP 3-5 (aOR=2.76 [95% CI 1.34-5.67] for men with 0-3 ejaculations/month) or with a locally advanced-metastatic tumor (aOR=4.70 [95% CI 1.55-14.29]). Moreover, men with moderate urinary symptoms and 0-3 ejaculations/month had the highest risk, aOR=3.83 (95% CI 1.84-7.95).A low EF could be associated with a higher risk of PCa, especially for cases with ISUP 3-5 or with a locally advanced-metastatic tumor.CONCLUSIONSA low EF could be associated with a higher risk of PCa, especially for cases with ISUP 3-5 or with a locally advanced-metastatic tumor.
To evaluate the association between ejaculation frequency (EF) during four stages of life and prostate cancer (PCa) according to tumor aggressiveness, PCa stage, and urinary symptomatology. A total of 456 incident PCa cases histologically confirmed, and 427 controls aged 40-80 years from the CAPLIFE study were analyzed. This study is a population-based case-control study carried out in the south of Spain. Average EF was measured for: (1) 20s, (2) 30s, (3) 40s, and (4) one year before the interview. EF was categorized into: (1) 0-3, (2) 4, and (3) >4 ejaculations/month. Sociodemographic, lifestyle, and medical information were also collected. To estimate the association between EF and PCa, adjusted ORs (aORs) and 95% CIs were calculated by logistic regression models. A year before the interview, PCa cases ejaculated less frequently than the controls. An inverse association was observed between the EF a year before and PCa, aOR=1.64 (95% CI 1.03-2.61) for men with 4 ejaculations/month, and aOR=2.38 (95% CI 1.57-3.60) for men with 0-3 ejaculations/month, compared to men with >4. The association was higher for cases with ISUP 3-5 (aOR=2.76 [95% CI 1.34-5.67] for men with 0-3 ejaculations/month) or with a locally advanced-metastatic tumor (aOR=4.70 [95% CI 1.55-14.29]). Moreover, men with moderate urinary symptoms and 0-3 ejaculations/month had the highest risk, aOR=3.83 (95% CI 1.84-7.95). A low EF could be associated with a higher risk of PCa, especially for cases with ISUP 3-5 or with a locally advanced-metastatic tumor.
PurposeTo evaluate the association between ejaculation frequency (EF) during four stages of life and prostate cancer (PCa) according to tumor aggressiveness, PCa stage, and urinary symptomatology.Materials and MethodsA total of 456 incident PCa cases histologically confirmed, and 427 controls aged 40–80 years from the CAPLIFE study were analyzed. This study is a population-based case-control study carried out in the south of Spain. Average EF was measured for: (1) 20s, (2) 30s, (3) 40s, and (4) one year before the interview. EF was categorized into: (1) 0–3, (2) 4, and (3) >4 ejaculations/month. Sociodemographic, lifestyle, and medical information were also collected. To estimate the association between EF and PCa, adjusted ORs (aORs) and 95% CIs were calculated by logistic regression models.ResultsA year before the interview, PCa cases ejaculated less frequently than the controls. An inverse association was observed between the EF a year before and PCa, aOR=1.64 (95% CI 1.03–2.61) for men with 4 ejaculations/month, and aOR=2.38 (95% CI 1.57–3.60) for men with 0–3 ejaculations/month, compared to men with >4. The association was higher for cases with ISUP 3–5 (aOR=2.76 [95% CI 1.34–5.67] for men with 0–3 ejaculations/month) or with a locally advanced-metastatic tumor (aOR=4.70 [95% CI 1.55–14.29]). Moreover, men with moderate urinary symptoms and 0–3 ejaculations/month had the highest risk, aOR=3.83 (95% CI 1.84–7.95).ConclusionsA low EF could be associated with a higher risk of PCa, especially for cases with ISUP 3–5 or with a locally advanced-metastatic tumor.
Author Rodríguez-Barranco, Miguel
Olmedo-Requena, Rocío
Castillo-Bueno, Helga-María
Lozano-Lorca, Macarena
Barrios-Rodríguez, Rocío
Jiménez-Moleón, José Juan
Jiménez-Pacheco, Antonio
Vázquez-Alonso, Fernando
AuthorAffiliation 3 Departamento de Medicina Preventiva y Salud Pública, Universidad de Granada, Granada, Spain
1 Departamento de Enfermería, Faculty of Health Sciences of Ceuta, Universidad de Granada, Ceuta, Spain
5 Department of Urology, Clínico San Cecilio University Hospital, Granada, Spain
6 Department of Urology, Virgen de las Nieves University Hospital, Granada, Spain
8 Andalusian School of Public Health (EASP), Granada, Spain
2 Instituto de Investigación Biosanitaria ibs. GRANADA, Granada, Spain
7 Maracena Primary Health Care Centre, Distrito Sanitario Granada-Metropolitano, Granada, Spain
4 Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública, Instituto de Salud Carlos III, Madrid, Spain
AuthorAffiliation_xml – name: 6 Department of Urology, Virgen de las Nieves University Hospital, Granada, Spain
– name: 1 Departamento de Enfermería, Faculty of Health Sciences of Ceuta, Universidad de Granada, Ceuta, Spain
– name: 5 Department of Urology, Clínico San Cecilio University Hospital, Granada, Spain
– name: 2 Instituto de Investigación Biosanitaria ibs. GRANADA, Granada, Spain
– name: 7 Maracena Primary Health Care Centre, Distrito Sanitario Granada-Metropolitano, Granada, Spain
– name: 4 Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública, Instituto de Salud Carlos III, Madrid, Spain
– name: 3 Departamento de Medicina Preventiva y Salud Pública, Universidad de Granada, Granada, Spain
– name: 8 Andalusian School of Public Health (EASP), Granada, Spain
Author_xml – sequence: 1
  givenname: Macarena
  orcidid: 0000-0001-5282-814X
  surname: Lozano-Lorca
  fullname: Lozano-Lorca, Macarena
  organization: Departamento de Enfermería, Faculty of Health Sciences of Ceuta, Universidad de Granada, Ceuta, Spain., Instituto de Investigación Biosanitaria ibs. GRANADA, Granada, Spain
– sequence: 2
  givenname: Rocío
  orcidid: 0000-0003-0054-6700
  surname: Olmedo-Requena
  fullname: Olmedo-Requena, Rocío
  organization: Instituto de Investigación Biosanitaria ibs. GRANADA, Granada, Spain., Departamento de Medicina Preventiva y Salud Pública, Universidad de Granada, Granada, Spain., Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública, Instituto de Salud Carlos III, Madrid, Spain
– sequence: 3
  givenname: Rocío
  orcidid: 0000-0002-8772-636X
  surname: Barrios-Rodríguez
  fullname: Barrios-Rodríguez, Rocío
  organization: Instituto de Investigación Biosanitaria ibs. GRANADA, Granada, Spain., Departamento de Medicina Preventiva y Salud Pública, Universidad de Granada, Granada, Spain., Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública, Instituto de Salud Carlos III, Madrid, Spain
– sequence: 4
  givenname: Antonio
  orcidid: 0000-0002-8821-899X
  surname: Jiménez-Pacheco
  fullname: Jiménez-Pacheco, Antonio
  organization: Department of Urology, Clínico San Cecilio University Hospital, Granada, Spain
– sequence: 5
  givenname: Fernando
  orcidid: 0000-0003-3819-3832
  surname: Vázquez-Alonso
  fullname: Vázquez-Alonso, Fernando
  organization: Department of Urology, Virgen de las Nieves University Hospital, Granada, Spain
– sequence: 6
  givenname: Helga-María
  orcidid: 0000-0003-2260-1600
  surname: Castillo-Bueno
  fullname: Castillo-Bueno, Helga-María
  organization: Maracena Primary Health Care Centre, Distrito Sanitario Granada-Metropolitano, Granada, Spain
– sequence: 7
  givenname: Miguel
  orcidid: 0000-0002-9972-9779
  surname: Rodríguez-Barranco
  fullname: Rodríguez-Barranco, Miguel
  organization: Instituto de Investigación Biosanitaria ibs. GRANADA, Granada, Spain., Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública, Instituto de Salud Carlos III, Madrid, Spain., Andalusian School of Public Health (EASP), Granada, Spain
– sequence: 8
  givenname: José Juan
  orcidid: 0000-0001-7917-6145
  surname: Jiménez-Moleón
  fullname: Jiménez-Moleón, José Juan
  organization: Departamento de Enfermería, Faculty of Health Sciences of Ceuta, Universidad de Granada, Ceuta, Spain., Instituto de Investigación Biosanitaria ibs. GRANADA, Granada, Spain., Departamento de Medicina Preventiva y Salud Pública, Universidad de Granada, Granada, Spain
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37118956$$D View this record in MEDLINE/PubMed
BookMark eNptks1rGzEQxUVJSFI3p97LQi-F4nSk1WcvJRi7NRgaaHMWWkmb7LKWUq22xf99lTguSaguEqPfPB7z5jU6CjF4hN5iuGCspp_-9NvbC0KAYP4KnREixZxyBUeHNwF5is7HsYdyJIAAfIJOa4GxVIyfIbnsjZ0Gk7sYqlXyvyYf7K4ywVVXKY7ZZF8tTLA-fa4Wl1eb9WpZ_ciT271Bx60ZRn_-eM_Q9Wr5c_Ftvvn-db243MwtFTzPXc1kzYBahwWAJWDaRlFJPLOYOYuFkSBxA1AbrwwjhGNPW1Fz3ArFpK1naL3XddH0-i51W5N2OppOPxRiutEm5c4OXrdMtp6W7tZK2gKW4ImitLGKgXKuKVpf9lp3U7P1zvqQkxmeiT7_Cd2tvom_NYYaBC8Dn6EPjwopllGNWW-70fphMMHHadREglBYCg4Fff8C7eOUQplVoWqJuRKUFOrdU0v_vBwSKgDeA7bEMSbfatvlh7iKw24o1vT9Iuj7RdD7RSg9H1_0HGT_R_8FvKCxVw
CitedBy_id crossref_primary_10_3390_cancers17050843
crossref_primary_10_1016_j_clgc_2024_01_015
crossref_primary_10_3390_nu16060836
Cites_doi 10.1111/joim.12850
10.1007/s40121-021-00481-z
10.1093/acprof:oso/9780199754038.001.0001
10.1038/s41568-020-0267-9
10.3322/caac.21660
10.1111/jsm.12461
10.3390/nu12030768
10.1016/j.euf.2018.02.007
10.14740/wjon1191
10.1158/1078-0432.CCR-18-0370
10.1007/s10286-020-00724-y
10.3390/medicines8060030
10.4081/aiua.2017.1.75
10.1002/ijc.30471
10.1016/j.euf.2017.11.004
10.1001/jama.291.13.1578
10.1038/sj.pcan.4500954
10.3390/ijerph17176300
10.1097/MOU.0000000000000460
10.1016/j.envint.2021.106825
10.15585/mmwr.mm6941a1
10.1016/j.canep.2014.06.002
10.1097/PAS.0000000000000530
10.1016/j.urolonc.2017.03.007
10.1016/j.eururo.2016.03.027
10.1016/j.gaceta.2012.05.013
10.1016/j.jsxm.2018.07.004
10.1016/j.mehy.2008.03.039
ContentType Journal Article
Copyright Copyright © 2023 Korean Society for Sexual Medicine and Andrology.
2023. This work is published under http://creativecommons.org/licenses/by-nc/4.0 (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright © 2023 Korean Society for Sexual Medicine and Andrology 2023 Korean Society for Sexual Medicine and Andrology
Copyright_xml – notice: Copyright © 2023 Korean Society for Sexual Medicine and Andrology.
– notice: 2023. This work is published under http://creativecommons.org/licenses/by-nc/4.0 (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: Copyright © 2023 Korean Society for Sexual Medicine and Andrology 2023 Korean Society for Sexual Medicine and Andrology
DBID AAYXX
CITATION
NPM
7R6
888
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
PHGZM
PHGZT
PIMPY
PKEHL
PMKZF
PQEST
PQGEN
PQQKQ
PQUKI
PRINS
QXPDG
7X8
5PM
DOA
DOI 10.5534/wjmh.220216
DatabaseName CrossRef
PubMed
ProQuest GenderWatch
GenderWatch (Alumni Edition)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central Database Suite (ProQuest)
ProQuest One Community College
ProQuest Central
Proquest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Digital Collections
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Women's Studies
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
Diversity Collection
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
GenderWatch (Alumni Edition)
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Central China
ProQuest Central
ProQuest Digital Collections
GenderWatch
ProQuest One Academic UKI Edition
Diversity Collection
ProQuest Central Korea
ProQuest Women's & Gender Studies
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
PubMed
Publicly Available Content Database
Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Public Health
EISSN 2287-4690
EndPage 733
ExternalDocumentID oai_doaj_org_article_f58fe44f7fc84f0180e2944bc9509ddb
PMC10307655
37118956
10_5534_wjmh_220216
Genre Journal Article
GrantInformation_xml – fundername: Regional Ministry of Health and Families of Andalusia/Consejería de Salud y Familias, Junta de Andalucía
  grantid: PI-0514-2016
– fundername: ;
  grantid: PI-0514-2016
GroupedDBID 5-W
53G
7R6
8JR
8XY
AAKDD
AAYXX
ABDBF
ACUHS
ADBBV
ADRAZ
AEGXH
AFKRA
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
BENPR
CCPQU
CITATION
DIK
EF.
GROUPED_DOAJ
GX1
HYE
IPNFZ
KQ8
M48
PGMZT
PHGZM
PHGZT
PIMPY
PMKZF
QXPDG
RIG
RPM
NPM
ABUWG
AZQEC
DWQXO
PKEHL
PQEST
PQGEN
PQQKQ
PQUKI
PRINS
7X8
PUEGO
5PM
ID FETCH-LOGICAL-c476t-d3583504cd1700c20afb9482e5c15dc17a8081b003ae9a52261e4f7361f7958c3
IEDL.DBID M48
ISSN 2287-4208
IngestDate Wed Aug 27 01:31:17 EDT 2025
Thu Aug 21 18:37:46 EDT 2025
Fri Sep 05 09:52:50 EDT 2025
Mon Jun 30 03:45:33 EDT 2025
Mon Jul 21 05:28:04 EDT 2025
Thu Apr 24 23:10:42 EDT 2025
Tue Jul 01 02:42:49 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords Case-control studies
Sexual activity
CAPLIFE study
Prostate cancer
Ejaculation
Language English
License Copyright © 2023 Korean Society for Sexual Medicine and Andrology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c476t-d3583504cd1700c20afb9482e5c15dc17a8081b003ae9a52261e4f7361f7958c3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-9972-9779
0000-0001-7917-6145
0000-0003-0054-6700
0000-0002-8772-636X
0000-0002-8821-899X
0000-0003-3819-3832
0000-0001-5282-814X
0000-0003-2260-1600
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.5534/wjmh.220216
PMID 37118956
PQID 2838169742
PQPubID 6469029
PageCount 10
ParticipantIDs doaj_primary_oai_doaj_org_article_f58fe44f7fc84f0180e2944bc9509ddb
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10307655
proquest_miscellaneous_2807918760
proquest_journals_2838169742
pubmed_primary_37118956
crossref_citationtrail_10_5534_wjmh_220216
crossref_primary_10_5534_wjmh_220216
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-07-01
PublicationDateYYYYMMDD 2023-07-01
PublicationDate_xml – month: 07
  year: 2023
  text: 2023-07-01
  day: 01
PublicationDecade 2020
PublicationPlace Korea (South)
PublicationPlace_xml – name: Korea (South)
– name: Busan
PublicationTitle The world journal of men's health
PublicationTitleAlternate World J Mens Health
PublicationYear 2023
Publisher Korean Society for Sexual Medicine and Andrology
Publisher_xml – name: Korean Society for Sexual Medicine and Andrology
References Togawa (10.5534/wjmh.220216_ref6) 2021; 157
Epstein (10.5534/wjmh.220216_ref19) 2016; 40
Rao (10.5534/wjmh.220216_ref25) 2008; 71
de Bono (10.5534/wjmh.220216_ref23) 2020; 20
Kamiya (10.5534/wjmh.220216_ref26) 2021; 31
Mirone (10.5534/wjmh.220216_ref28) 2017; 89
Leitzmann (10.5534/wjmh.220216_ref12) 2004; 291
Sung (10.5534/wjmh.220216_ref2) 2021; 71
Svatek (10.5534/wjmh.220216_ref24) 2007; 10
Horwitz (10.5534/wjmh.220216_ref7) 2019; 285
Phua (10.5534/wjmh.220216_ref22) 2021; 8
10.5534/wjmh.220216_ref17
Nair-Shalliker (10.5534/wjmh.220216_ref9) 2017; 140
Olmedo-Requena (10.5534/wjmh.220216_ref16) 2020; 12
Brookman-May (10.5534/wjmh.220216_ref13) 2019; 5
De Nunzio (10.5534/wjmh.220216_ref14) 2017; 3
Whelan (10.5534/wjmh.220216_ref29) 2021; 10
Siegel (10.5534/wjmh.220216_ref3) 2020; 69
Caini (10.5534/wjmh.220216_ref30) 2014; 38
Rider (10.5534/wjmh.220216_ref11) 2016; 70
Ballon-Landa (10.5534/wjmh.220216_ref5) 2018; 28
Lozano-Lorca (10.5534/wjmh.220216_ref15) 2020; 17
Barber (10.5534/wjmh.220216_ref4) 2018; 24
Rawla (10.5534/wjmh.220216_ref1) 2019; 10
Willett (10.5534/wjmh.220216_ref21) 2012
Román Viñas (10.5534/wjmh.220216_ref20) 2013; 27
Papa (10.5534/wjmh.220216_ref10) 2017; 35
Lee (10.5534/wjmh.220216_ref27) 2014; 11
Vela Navarrete (10.5534/wjmh.220216_ref18) 1994; 18
Jian (10.5534/wjmh.220216_ref8) 2018; 15
References_xml – volume: 285
  start-page: 333
  year: 2019
  ident: 10.5534/wjmh.220216_ref7
  publication-title: J Intern Med
  doi: 10.1111/joim.12850
– volume: 10
  start-page: 1887
  year: 2021
  ident: 10.5534/wjmh.220216_ref29
  publication-title: Infect Dis Ther
  doi: 10.1007/s40121-021-00481-z
– volume-title: Nutritional epidemiology
  year: 2012
  ident: 10.5534/wjmh.220216_ref21
  doi: 10.1093/acprof:oso/9780199754038.001.0001
– volume: 20
  start-page: 455
  year: 2020
  ident: 10.5534/wjmh.220216_ref23
  publication-title: Nat Rev Cancer
  doi: 10.1038/s41568-020-0267-9
– volume: 71
  start-page: 209
  year: 2021
  ident: 10.5534/wjmh.220216_ref2
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21660
– volume: 11
  start-page: 1512
  year: 2014
  ident: 10.5534/wjmh.220216_ref27
  publication-title: J Sex Med
  doi: 10.1111/jsm.12461
– volume: 12
  start-page: 768
  year: 2020
  ident: 10.5534/wjmh.220216_ref16
  publication-title: Nutrients
  doi: 10.3390/nu12030768
– volume: 5
  start-page: 756
  year: 2019
  ident: 10.5534/wjmh.220216_ref13
  publication-title: Eur Urol Focus
  doi: 10.1016/j.euf.2018.02.007
– volume: 10
  start-page: 63
  year: 2019
  ident: 10.5534/wjmh.220216_ref1
  publication-title: World J Oncol
  doi: 10.14740/wjon1191
– volume: 24
  start-page: 5910
  year: 2018
  ident: 10.5534/wjmh.220216_ref4
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-18-0370
– volume: 31
  start-page: 165
  year: 2021
  ident: 10.5534/wjmh.220216_ref26
  publication-title: Clin Auton Res
  doi: 10.1007/s10286-020-00724-y
– volume: 8
  start-page: 30
  year: 2021
  ident: 10.5534/wjmh.220216_ref22
  publication-title: Medicines (Basel)
  doi: 10.3390/medicines8060030
– volume: 89
  start-page: 75
  year: 2017
  ident: 10.5534/wjmh.220216_ref28
  publication-title: Arch Ital Urol Androl
  doi: 10.4081/aiua.2017.1.75
– volume: 140
  start-page: 565
  year: 2017
  ident: 10.5534/wjmh.220216_ref9
  publication-title: Int J Cancer
  doi: 10.1002/ijc.30471
– volume: 3
  start-page: 352
  year: 2017
  ident: 10.5534/wjmh.220216_ref14
  publication-title: Eur Urol Focus
  doi: 10.1016/j.euf.2017.11.004
– volume: 18
  start-page: 841
  year: 1994
  ident: 10.5534/wjmh.220216_ref18
  publication-title: Actas Urol Esp
– volume: 291
  start-page: 1578
  year: 2004
  ident: 10.5534/wjmh.220216_ref12
  publication-title: JAMA
  doi: 10.1001/jama.291.13.1578
– volume: 10
  start-page: 279
  year: 2007
  ident: 10.5534/wjmh.220216_ref24
  publication-title: Prostate Cancer Prostatic Dis
  doi: 10.1038/sj.pcan.4500954
– volume: 17
  start-page: 6300
  year: 2020
  ident: 10.5534/wjmh.220216_ref15
  publication-title: Int J Environ Res Public Health
  doi: 10.3390/ijerph17176300
– volume: 28
  start-page: 55
  year: 2018
  ident: 10.5534/wjmh.220216_ref5
  publication-title: Curr Opin Urol
  doi: 10.1097/MOU.0000000000000460
– volume: 157
  start-page: 106825
  year: 2021
  ident: 10.5534/wjmh.220216_ref6
  publication-title: Environ Int
  doi: 10.1016/j.envint.2021.106825
– volume: 69
  start-page: 1473
  year: 2020
  ident: 10.5534/wjmh.220216_ref3
  publication-title: MMWR Morb Mortal Wkly Rep
  doi: 10.15585/mmwr.mm6941a1
– volume: 38
  start-page: 329
  year: 2014
  ident: 10.5534/wjmh.220216_ref30
  publication-title: Cancer Epidemiol
  doi: 10.1016/j.canep.2014.06.002
– ident: 10.5534/wjmh.220216_ref17
– volume: 40
  start-page: 244
  year: 2016
  ident: 10.5534/wjmh.220216_ref19
  publication-title: Am J Surg Pathol
  doi: 10.1097/PAS.0000000000000530
– volume: 35
  start-page: 530.e7
  year: 2017
  ident: 10.5534/wjmh.220216_ref10
  publication-title: Urol Oncol
  doi: 10.1016/j.urolonc.2017.03.007
– volume: 70
  start-page: 974
  year: 2016
  ident: 10.5534/wjmh.220216_ref11
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2016.03.027
– volume: 27
  start-page: 254
  year: 2013
  ident: 10.5534/wjmh.220216_ref20
  publication-title: Gac Sanit
  doi: 10.1016/j.gaceta.2012.05.013
– volume: 15
  start-page: 1300
  year: 2018
  ident: 10.5534/wjmh.220216_ref8
  publication-title: J Sex Med
  doi: 10.1016/j.jsxm.2018.07.004
– volume: 71
  start-page: 442
  year: 2008
  ident: 10.5534/wjmh.220216_ref25
  publication-title: Med Hypotheses
  doi: 10.1016/j.mehy.2008.03.039
SSID ssj0000800701
Score 2.256163
Snippet To evaluate the association between ejaculation frequency (EF) during four stages of life and prostate cancer (PCa) according to tumor aggressiveness, PCa...
PurposeTo evaluate the association between ejaculation frequency (EF) during four stages of life and prostate cancer (PCa) according to tumor aggressiveness,...
Purpose: To evaluate the association between ejaculation frequency (EF) during four stages of life and prostate cancer (PCa) according to tumor aggressiveness,...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 724
SubjectTerms Alcohol
caplife study
case-control studies
Diabetes
ejaculation
Erectile dysfunction
Family medical history
Hospitals
Longitudinal studies
Original
Prostate cancer
Questionnaires
sexual activity
Sexual behavior
Sociodemographics
Tumors
Urology
Vasectomy
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Na9wwEB1CToVQmjZt3aRFgZwKbixbsqTe0mWXpJSQQwO5GX2SLq1TthtK_n1nLGfZDYFcerUElmcs6z1r9B7AUaWNJCmusoo8lEJKWzpJloAK4YJHjuHDUG1x3p5eiq9X8mrN6otqwrI8cA7ccZI6RSGSSl6LRHJTsTZCOI_3MCE4-vpWplojU_MRB6nB-7hGSlDSHnI-nCdlI47_zn9df6qR9pPL-dpyNKj2PwY1H1ZMri1BsxfwfMSO7CSPeRe2Yv8SdvKPN5bPE70CPZ1bP3pysdkiV0rfMdsHdkEnPBBbsgmlevGZTU4uvp3NpoyKCe_24HI2_T45LUd7hNIL1S7L0EiET5XwgTT2fF3Z5IzQdZSey-C5suSqQdPWRmMJZ_GIcWxanpSR2jevYbu_6eNbYNw541QylsskfFQOSYT2wgurU0DMUMDH-yh1ftQOJwuLnx1yCAppRyHtckgLOFp1_p0lMx7v9oXCvepCOtfDBcx-N2a_eyr7BRzcJ6sbJ9-fDhGT5i0SpbqAw1UzThvaC7F9vLmlPpUyHJeCqoA3OberkTQKWRfyxgL0RtY3hrrZ0v-4HqS5ybRNtVK--x8Ptw_PyNw-FwcfwPZycRvfIwRaug_D2_4PmU0BRg
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Central Database Suite (ProQuest)
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3daxQxEB_q9UUQ8dvVKhH6JKzdj2STCCLtcUcVOQ6x0Lcln61F9-p5RfrfO7NfelJ83c3DMJkkv0lmfj-A_UxpQVRcaRZyn3IhTGoFSQJKhAsOcwzn22qLRXV8wj-eitMdWAy9MFRWOeyJ7UbtV47uyA_wGFR5hei3eH_5IyXVKHpdHSQ0TC-t4N-1FGO3YBe3ZJFNYPdotlh-Hm9dCB_JVhO5wFQhpbflrmlPiJIf_Lr4fv6mKND2auuYatn8b4Kg_1ZS_nU0ze_B3R5TssMuCO7DTmgewJ3uQo51fUYPQc0ujOu1uth83VVQXzPTeLakzg_EnGxKIbB-y6aHy08f5jNGRYbXj-BkPvsyPU572YTUcVltUl8KhFUZd56491yRmWg1V0UQLhfe5dKQ2gYtZxO0IfyVBx5lWeVRaqFc-RgmzaoJT4Hl1moroza5iNwFaTG5UI47blT0iCUSeD14qXY9pzhJW3yrMbcgl9bk0rpzaQL74-DLjkrj5mFH5O5xCPFftx9W67O6X051FCoGjlZHp3gkErJQaM6tw8jT3tsE9obJqvtF-bP-E0IJvBp_43KiNxLThNUVjcmkzvGIyBJ40s3taEkpMRvDfDIBtTXrW6Zu_2m-nreU3STmJishnv3frudwm-Tsu3LgPZhs1lfhBYKejX3ZR_Jvsx7-tg
  priority: 102
  providerName: ProQuest
Title Ejaculation Frequency and Prostate Cancer: CAPLIFE Study
URI https://www.ncbi.nlm.nih.gov/pubmed/37118956
https://www.proquest.com/docview/2838169742
https://www.proquest.com/docview/2807918760
https://pubmed.ncbi.nlm.nih.gov/PMC10307655
https://doaj.org/article/f58fe44f7fc84f0180e2944bc9509ddb
Volume 41
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fa9swED669mUwxn7PXRc86NPAmWVLltSX0oaEbowSxgJ9M5IsrQuds3kpXf773dlOWErYqyXDcadD3yed7gM4TpUW1IorST2rEi6ESawgSUCJcMEhx3BVW21xWVzM-KcrcbUHazHO3oG_d1I70pOaNTfDP79Wp5jwiF-HQuT8w938x_UwQxbPigdw0F4UUQ1fj_PnPSySrRRyhgwhoSvl7q3e_f-3dqe2if8u5Hm_gPKfHWnyBB73UDI-62L_FPZ8_Qwededwcfe86Dmo8dy4XqIrnjRd4fQqNnUVT-nBB0LNeESRb07i0dn088fJOKbawtULmE3GX0cXSa-WkDgui2VS5QLRVMpdRS33XJaaYDVXmReOicoxaUhkg7LYeG0IdjHPg8wLFqQWyuUvYb9e1P41xMxabWXQhonAnZcWOYVy3HGjQoUQIoL3ay-Vrm8lTooWNyVSCnJpSS4tO5dGcLyZ_LProLF72jm5ezOF2l63HxbNt7LPojIIFTxHq4NTPFDvMZ9pzq3DBaerykZwtA5WuV5KJQIoxQrkTVkE7zbDmEV0NWJqv7ilOanUDHeGNIJXXWw3luQSSRjSyAjUVtS3TN0eqb9ft526ScNNFkIc_t-uN_CQVOy7KuAj2F82t_4tYp2lHcDB-fhy-mXQnhUM2lX9F51a_Ro
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3daxNBEB9q-qAg4renVVeoL8LZ-9i9vROKtDEhsTEEaaFv595-WIteappS8s_5tzlzXxopvvX1djmWmdnd38zOzA9gO0gzQa24_MCGxudCKL8QRAkoES5o9DG0qbItpsnoiH88Fscb8KuthaG0yvZMrA5qM9cUI9_BazANE0S_0fuznz6xRtHrakuhoRpqBbNbtRhrCjsO7OoSXbjz3fEH1PfrKBoODvsjv2EZ8DWXydI3sUAUEnBtqFWdjgLlioynkRU6FEaHUhE5BVm_spkiuBJa7mSchE5mItUx_vcGbHIKoPRgc38wnX3uojyEx2TFwRyha-LTW3ZdJChEzHcuT3-cvI0ilFWydi1W7AFXQd5_Mzf_ugqHd-FOg2HZXm1092DDlvfhdh0AZHVd0wNIB6dKN9xgbLioM7ZXTJWGzajSBDEu65PJLd6x_t5sMh4OGCU1rh7C0bUI8BH0ynlpnwALiyIrpMtUKBzXVhbozKSaa65SZxC7ePCmlVKumx7mRKXxPUdfhkSak0jzWqQebHeTz-rWHVdP2ydxd1Oo33b1Yb74mjfbN3cidZbjqp1OuaOmZzbKOC80WnpmTOHBVqusvDkEzvM_JuvBq24Yty-9yajSzi9oTiCzEK-kwIPHtW67lcQSvT_0Xz1I17S-ttT1kfLbSdUinMjjZCLE0_-v6yXcHB1-muST8fTgGdxCecR1KvIW9JaLC_scAdeyeNFYNYMv172RfgNKazna
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1ta9RAEB5qCyKI-G60aoT6RYiXl91sIhRprxd6thyHWOi3dLMv1qK5er1S7i_6q5xJNtGT4rd-zS5hmZ3ZeWZ3Zh6ArTDLObXiCkIT6YBxLoOKEyWgQLigMMZQusm2mKT7R-zTMT9eg19dLQylVXZnYnNQ65miO_IBusEsShH9xgPr0iKme8XH858BMUjRS2tHpyEdzYLebtqNuSKPA7O8wnDuYnu8h3v_No6L0ZfhfuAYBwLFRLoIdMIRkYRMaWpbp-JQ2ipnWWy4irhWkZBEVEGWIE0uCbpEhlmRpJEVOc9Ugv-9BRsCvT4Gghu7o8n0c3_jQ9hMNHzMMYYpAb1rtwWDnCdscHX24_R9HKPc0hUX2TAJXAd__83i_MstFvfhnsOz_k6rgA9gzdQP4W57Gei3NU6PIBudSeV4wvxi3mZvL31Za39KVSeId_0hqd_8gz_cmR6Oi5FPCY7Lx3B0IwJ8Auv1rDbPwI-qKq-EzWXELVNGVBjYZIopJjOrEcd48K6TUqlcP3Oi1fheYlxDIi1JpGUrUg-2-snnbRuP66ftkrj7KdR7u_kwm38tnSmXlmfWMFy1VRmz1ADNxDljlUKtz7WuPNjsNqt0B8JF-Ud9PXjTD6Mp0_uMrM3skuaEIo_QPYUePG33tl9JIjASxFjWg2xl11eWujpSfztt2oUTkZxIOX_-_3W9httoUOXheHLwAu6gOJI2K3kT1hfzS_MSsdeieuWU2oeTm7aj3y54Ph4
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Ejaculation+Frequency+and+Prostate+Cancer%3A+CAPLIFE+Study&rft.jtitle=The+world+journal+of+men%27s+health&rft.au=Lozano-Lorca%2C+Macarena&rft.au=Olmedo-Requena%2C+Roc%C3%ADo&rft.au=Barrios-Rodr%C3%ADguez%2C+Roc%C3%ADo&rft.au=Jim%C3%A9nez-Pacheco%2C+Antonio&rft.date=2023-07-01&rft.pub=Korean+Society+for+Sexual+Medicine+and+Andrology&rft.issn=2287-4208&rft.eissn=2287-4690&rft.volume=41&rft.issue=3&rft.spage=724&rft_id=info:doi/10.5534%2Fwjmh.220216&rft.externalDBID=HAS_PDF_LINK
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2287-4208&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2287-4208&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2287-4208&client=summon